

Defining life's signals

FY26 was a record year: sales up 18.5%, EBITDA up 74%, back in profit and generating cash. In FY27 we aim to grow sales by double digits again and lift margins further.

\$60.3M

FY26 sales - a record, up 18.5%

\$5.4M

FY26 EBITDA, up 74%

\$6.6M

Cash from operations, up from \$0.4M

Compumedics Limited (ASX: CMP)

All figures are in Australian dollars unless otherwise stated. This presentation was authorised for release by the Board of Compumedics Limited.



A global medical technology company with six revenue segments - now entering a new phase of growth

Compumedics makes the equipment and software doctors use to diagnose sleep disorders, monitor the brain and measure blood flow in the brain. Founded in Melbourne in 1987 and listed on the ASX in 2000, we sell direct in Australia, the United States and Europe and through distributors in more than 100 countries. Our products are backed by decades of clinical evidence and an installed base of more than 25,000 systems.



Our technology is used by leading hospitals and research institutions worldwide.

Our plan is simple: sell more software and consumables to the customers we already have, grow in the largest markets - led by the U.S. - and turn sales growth into higher margins and cash.

THE PLATFORM AT A GLANCE

25,000+

Installed systems

In 60+ countries - the base for repeat software, consumables and service revenue

100+

Distribution markets

Direct sales teams in Asia Pacific, the U.S. and Europe

~175

People in six countries

All in fully owned local subsidiaries

39 years

Of platform building

Founded 1987; listed on the ASX since 2000

SIX REVENUE SEGMENTS, ONE PLATFORM

Sleep - clinical diagnostics	Sleep-lab systems (Grael, PSG) used by hospitals and clinics
Somfit & Nexus 360 SaaS	Home sleep tests, wearables and cloud software - paid for per study
Neuro monitoring & research	Clinical EEG, Okti wireless monitoring, and Neuroscan / CURRY brain research software
MEG	Orion LifeSpan brain imaging - high-value systems, driven by our CURRY brain analysis software
DWL bloodflow & TCD	Ultrasound (transcranial Doppler) that measures blood flow in the brain
Consumables & customer care	Electrodes, sensors, disposables, service and support - repeat revenue

FY26 in short: record sales, profit up sharply and much stronger cash



SALES ORDERS

\$62.7M

Orders slightly ahead of sales (1.04x)

\$28.3M of orders still to deliver in FY27



SALES REVENUE - A RECORD

\$60.3M

Up +18.5% on FY25

Up +21% on FY24



EBITDA

\$5.4M

Up +74.3% on FY25

9% margin; net profit back in the black

Profit grew faster than sales

EBITDA grew four times faster than sales and the margin rose to 9%. Extra sales flow through to profit because the global platform - technology, manufacturing and sales teams - is already in place.

More of our revenue repeats

Somfit & Nexus 360 software revenue grew 70% to \$10.2M - now 17% of sales. Recurring revenue (software, consumables and service) is 30% of the total. MEG delivered \$9.7M, with \$13.1M of MEG orders still to deliver.

Balance sheet stronger


Cash from operations rose to \$6.6M (FY25: \$0.4M). Net cash after the invoice-financing facility and overdraft improved by \$6.7M to \$5.6M. The \$2M cost-savings program was delivered while we kept investing in growth.

The result Compumedics enters FY27 bigger, with better-quality revenue, more cash and a clearer view of the year ahead.

FY27: double-digit sales growth, wider margins, and three clear steps from a platform that already works

Sales revenue (\$M)


Objective: another year of double-digit growth



FY26 sales grew 18.5%. \$28.3M of orders were already in hand at the start of FY27, giving good visibility over the year.

EBITDA (\$M) and EBITDA margin

Objective: EBITDA to grow faster than sales - margin expands



The platform is already built, so each extra dollar of sales carries little extra fixed cost. FY26 EBITDA grew 74% on 18.5% sales growth.

THREE STEPS FROM A PROVEN PLATFORM

01 Grow Somfit in the U.S.

Home sleep testing is the fastest-growing part of the U.S. sleep market and Somfit tests are already reimbursed there. Software revenue grew 70% in FY26; Somfit D is heading for U.S. release.

02 Stay #1 in premium sleep labs

Compumedics holds about 35% of the global premium sleep-lab market. FY27 is about defending that position as testing shifts into the home, and delivering \$18.2M of sleep-lab orders.

03 Expand MEG into the U.S. market

Six Orion LifeSpan sales orders in China and \$13.1M of MEG orders in hand. U.S. research hospitals are expected to start ordering in FY27, with first installations in FY28.

The plan Double-digit sales growth, EBITDA growing faster than sales, and three steps that build on what already works.

Light-blue FY27F bars are illustrative only, drawn at the low end of the Company's stated FY27 objective (sales growth of 10%+, EBITDA growing faster than sales) - not a forecast. Source: Business Update, 25 August 2026.

SECTION 01

The FY26 result


Record revenue, EBITDA up 74%, a return to profit and materially stronger cash generation - the year the operating model demonstrated its leverage.



Earnings momentum through revenue growth, recurring revenue expansion and cost discipline


Sales Orders (\$M)

1.04x book-to-bill; \$28.3M open orders into FY27




Sales Revenue (\$M)

Record revenue FY26, up +18.5% YoY




USA Revenue (\$M)

-6% YoY during the U.S. commercial reset; strong Somfit growth




Somfit & SaaS Sales Orders (\$M)

Up +58% YoY; SaaS revenue now 17% of total (12% in FY25)



EBITDA (\$M)

Up +74% YoY; margin 9% with expansion from operating leverage



KEY TAKEAWAYS

- Growth across almost every headline metric except U.S. revenue, where the commercial reset is complete
- EBITDA grew four times faster than revenue
- Recurring and software-enabled revenue is scaling ahead of the Group
- Structural tailwinds across sleep, neurology and neuroimaging markets

A step-change in earnings quality, profitability and cash generation

30 June FYE \$M	FY23A	FY24A	FY25A	FY26A
Sales Orders	42.5	51.9	63.4	62.7
<i>Growth YoY</i>	+12%	+22%	+22%	(1%)
Revenue Reported	42.4	49.7	50.8	60.3
<i>Growth YoY</i>	+12%	+17%	+2%	+18.5%
Gross Profit	21.6	26.0	27.9	31.0
<i>Gross Margin</i>	51%	52%	55%	51%
EBITDA	(2.0)	2.7	3.1	5.4
<i>EBITDA Margin</i>	(5%)	5%	6%	9%

Operating leverage demonstrated

Revenue up 18.5% and EBITDA up 74.3%, with margin lifting to 9% - evidence of the scalability of the operating model as revenue is spread across existing R&D, manufacturing and corporate infrastructure.

Profitability and cash restored

NPAT returned to positive territory and operating cash inflow rose to \$6.6M from \$0.4M, and cash less the invoice financing facility and overdraft improved by \$6.7 million to \$5.6 million.


Cost discipline maintained

The \$2M cost savings program was delivered - sales & marketing expenditure fell \$3.4M - while R&D investment in priority platforms continued.

The key financial message

FY26 demonstrated that Compumedics does not require revenue growth and cost growth to move in parallel. Increasing scale, recurring revenue and operating discipline provide the opportunity for earnings to compound faster than revenue.

\$14.2 million of growth from MEG, SaaS and consumables absorbed a temporary \$4.9 million decline in capital equipment



Growth is now concentrated

MEG and SaaS contributed \$13.9M of incremental revenue between them.

Two very different kinds of growth


MEG is lumpy, milestone-recognised and capital-intensive; SaaS is recurring, high-margin and compounding. The Group benefits from both - for different reasons.

The capital base is still the ballast

Sleep clinical, neuro and DWL remain \$32.3M of revenue and the installed base the recurring lines are sold into. Their FY26 decline is a conversion problem, not a demand problem.

EBITDA up 74%: gross profit growth, other income and delivered cost savings funded a step-up in expensed R&D

\$M | constructed from the audited FY26 income statement; components sum to reported FY25 and FY26 EBITDA; FX and D&A shown net.



The cost program is visible in the P&L

Sales & marketing expenditure fell \$3.4M to \$14.7M - driving the announced \$2M program.

R&D is an investment choice, not cost drift


R&D expense rose to \$4.8M as a higher proportion of development was expensed rather than capitalised; investment across priority platforms continued.

Margin recovery is the FY27 lever

Gross margin of 51% (FY25: 55%) reflects MEG mix, tariffs and input costs. Pricing actions, supply-chain efficiencies and product cost reductions target recovery.

A diversified revenue base across multiple geographies and segments

GEOGRAPHY - FY26 REVENUE



USA: Somfit-led growth; capital equipment reset underway with new commercial leadership in place


Europe: Direct DWL operations; FY26 affected by the timing of larger projects

Asia: China MEG expansion and large sleep distribution contracts

Australia: Somfit pharmacy partnership (Philips) driving HST adoption

Latin America & Middle East: Targeted distributor expansion

SEGMENT - FY26 REVENUE



Sleep - clinical diagnostics: High-end PSG systems for hospital and clinic sleep laboratories - the installed base the recurring lines are sold into

Somfit & Nexus 360 SaaS: Rapidly scaling home sleep testing and cloud workflow - built for the shift to home-based care

Neuro monitoring & research: Wireless EEG (Okti), Neuroscan and CURRY - trusted in epilepsy, brain-injury and research settings

MEG: Orion LifeSpan neuroimaging systems - high-value, milestone-recognised installations


DWL bloodflow & TCD: Real-time brain blood-flow monitoring; robotic TCD in disciplined development

Consumables & customer care: Recurring revenue from electrodes, disposables, service and support across the installed base

SECTION 02

The platform & growth engines

What Compumedics is, how 39 years of engineering built six revenue segments, the markets they address - and where each is heading in FY27.



Three eras of value creation: an engineering contract, an acquisition platform, and an emerging subscription business

01

1986 - 2000

The founding insight

Solve one hospital's problem, then export it. Epworth Hospital commissions a computerised sleep laboratory (1986); Compumedics is founded in 1987. NASA contracts and the world's largest sleep study follow; FDA clearance in 1997; Australian Exporter of the Year in 1998; ASX listing in December 2000.

02

2001 - 2020

Building the platform


Acquire the adjacency, keep the brand, sell it through one global channel. Neuroscan (2002) brings research EEG and CURRY, the gold-standard source-localisation software; DWL (2004) brings transcranial Doppler; the KRISS licence (2016) becomes the Orion LifeSpan MEG, FDA-cleared in 2020.

03

2021 - 2026

From boxes to subscriptions

Regulatory clearances turn hardware into a per-study annuity. Nexus 360 moves clinic workflow to the cloud; Okti and Somfit are FDA-cleared in 2023; Philips pharmacy distribution and single-use Somfit D follow in 2025. FY26: record revenue of \$60.3M, with SaaS up ~70%.



The pattern across all three eras: Compumedics has never bought market share. Each of its four platforms began as a technical problem no incumbent had solved economically. Since listing in December 2000 the Company has generated almost \$960M of cumulative revenue, more than \$750M of it from exports.

56 times lighter in 30 years - the precondition for selling studies instead of boxes

Regulatory clearance opened the market; miniaturisation is what made the study itself sellable - and a study is what you can sell by subscription.



Square area proportional to published device weight | 56× lighter across 30 years



P-Series (1995): World's first portable sleep monitoring system



Okti (2023): EEG left the ward



Somfit (2023) and Somfit D (2026)




MEG (2019): the deliberate exception - dual adult/paediatric helmets


A large, under-diagnosed market shifting toward home-based, wearable and cloud-delivered care

THE ADDRESSABLE MARKETS - \$B

Home sleep testing +9.7% CAGR



Clinical EEG +10.2% CAGR



MEG +5.7% CAGR



THE UNDIAGNOSED POPULATION

936M adults worldwide have obstructive sleep apnoea - 425M moderate-to-severe - and 80-90% are undiagnosed.

THE STRUCTURAL SHIFT

From the laboratory to the home

Patient convenience, lower cost per study and supportive U.S. reimbursement are moving diagnostics into the home - the segment Somfit was built for.

Clinical grade beats wellness data

Consumer wearables are training patients to measure sleep; reimbursed care still requires clinical-grade, physician-read diagnostics.

Growing use in pharma trials

Sleep and neuro diagnostics are increasingly used in pharmaceutical research and clinical trials, adding a further source of demand.

U.S. HOME SLEEP TESTING



\$343M

annual U.S. home sleep testing market, growing at ~25% per annum

4M

home sleep studies performed in the U.S. each year

80%+

of U.S. sleep-disease patients remain untested; only 2-4M studies are run each year

CY27

federal review of home sleep testing reimbursement; existing codes already cover forehead-mounted tests

Why Compumedics wins Clinical-grade, reimbursable diagnostics rather than wellness data - delivered through a 25,000-system installed base and an integrated sleep-and-neuro platform that consumer wearables lack and incumbents cannot easily replicate.

Building a more recurring, visible and valuable revenue model

Compumedics has historically generated a significant proportion of revenue from sophisticated capital equipment. That installed base remains a competitive advantage - but the model is evolving: approximately 1,600 systems are sold each year across a 25,000-unit installed base, and the Group increasingly generates revenue throughout the customer lifecycle.

CAPITAL EQUIPMENT

Sleep - clinical diagnostics

\$16.1M (11%) YoY

Grael and laboratory PSG systems - the installed base the recurring lines are sold into.

RECURRING | COMPOUNDING

Somfit & Nexus 360 SaaS

\$10.2M +70% YoY

Revenue tied to each diagnostic study performed - 17% of FY26 revenue.

CAPITAL EQUIPMENT

Neuro monitoring & research

\$11.7M (18%) YoY

Clinical EEG, Okti wireless monitoring, Neuroscan and CURRY research systems.

RECURRING

Consumables & customer care

\$8.1M +4% YoY

Electrodes, sensors, disposables, service and support across the installed base.

CAPITAL EQUIPMENT

DWL bloodflow & TCD

\$4.5M (5%) YoY

Transcranial Doppler systems for non-invasive cerebral blood-flow monitoring.

CAPITAL EQUIPMENT

MEG

\$9.7M FY25: nil

Orion LifeSpan systems, high-value milestone-driven installations, complemented by CURRY, the established gold standard in neuroimaging software.


The strategic objective Increase the economic value of every installed system by expanding the recurring software, service and consumable revenue generated throughout its useful life - 30% of FY26 revenue recurred, up from 25% in FY24.

An established global sleep diagnostics business - and the foundation of the recurring model

FY26 revenue of \$16.1M, down 11% on a strong FY25. Sales orders of \$18.2M exceeded revenue - management attributes the shortfall to the timing of shipment and invoicing rather than demand.

The core business

Grael HD-PSG and laboratory systems hold the #1 position in premium hospital and clinic sleep labs worldwide (~35% share), with home sleep testing extending reach beyond the laboratory. FY26 revenue was \$16.1M (FY25: \$18.2M).



A conversion story, not a demand story

FY26 sales orders of \$18.2M - 29% of Group orders - exceeded segment revenue. The U.S. capital equipment reset is underway, with a U.S.-based sleep and neurology commercial leader appointed in April 2026.

The strategic role

Every system placed enlarges the installed base into which Somfit, Nexus 360, consumables and customer care are sold. The capital equipment business is the distribution channel for the recurring model - it is worth more to the Group than its own revenue line.


FY27 focus

Stay #1 in premium sleep labs: defend the high-end position as testing shifts into the home, convert \$18.2M of open orders into revenue, and restore U.S. capital equipment productivity - every lab system placed extends the base into which Somfit, Nexus 360 and consumables are sold.

Investor takeaway Sleep clinical diagnostics remains the Group's largest segment and its strategic foundation - the FY26 decline was timing-led, with orders of \$18.2M supporting recovery in FY27.

Somfit is evolving from a diagnostic device into a scalable digital sleep platform

Somfit & Nexus 360 SaaS revenue (\$M)



SaaS as a share of total revenue



Commercial momentum is now visible. SaaS revenue grew 70% in FY26 - achieved before Somfit D has been commercially released in the United States, and with Somfit already preferred in pharmaceutical trials and by sleep specialists. More than 910,000 combined Somfit and Nexus 360 cloud studies have been completed to date, 210,000 of them in FY26.

WHY THE MODEL IS STRATEGICALLY ATTRACTIVE

Recurring economics

Revenue is generated repeatedly as diagnostic studies are performed

Scalability

Software-enabled volume grows without a proportional increase in fixed infrastructure

Customer retention

Integration into clinical workflow increases switching costs

Installed-base leverage

Existing clinical relationships provide the channel for newer Somfit solutions

International optionality

Deployable progressively across multiple markets and distribution models

The U.S. opportunity for Somfit

Somfit tests are already reimbursed under existing U.S. codes and are preferred in pharmaceutical trials. Following Somfit D's FDA clearance we are targeting ~10% of the U.S. home sleep testing market - a \$143-286M incremental SaaS revenue opportunity over the next two years.



FY27 PRIORITIES

- Continue scaling Somfit and Nexus 360 SaaS revenues
- Expand U.S. adoption across home sleep testing providers
- Build on pharmacy-led home sleep testing in Australia, where Somfit holds over 75% of the pharmacy channel
- Deepen utilisation within existing enterprise customers
- Progress Somfit D toward U.S. commercial release
- Broaden the installed base and its recurring economics

A globally established neurotechnology platform supporting growth, cross-sell and innovation

Products spanning EEG, Okti, Neuroscan and CURRY are used across clinical and research settings, supporting applications from epilepsy monitoring to advanced neuroscience research. Neuroscan systems alone are used in more than 1,500 universities and laboratories across 40+ countries.

STRATEGIC IMPORTANCE - MORE THAN STANDALONE PRODUCT REVENUE

Customer access

Relationships with neurologists, hospitals, universities and research institutions worldwide

Technology depth

Decades of signal-acquisition, analytics and neurophysiology expertise

Cross-selling potential

Shared customers across EEG, research systems and MEG

Recurring revenue

Consumables, software, service and system upgrades from the installed base

Innovation platform

Research capability that strengthens the Group's broader neurotechnology proposition

The platform in numbers

1,500+ research institutions | 40+ countries | full clinical EEG suite | Okti wireless EEG cleared by the FDA in 2023

FY27 FOCUS

- Improve U.S. capital equipment execution
- Expand penetration of differentiated wireless EEG technology
- Deepen relationships across key European and U.S. clinical markets

- Sell the broader portfolio alongside MEG opportunities
- Grow software and consumable revenues from the installed base



OrionMEG is transitioning into a high-value global commercial platform

The strategic significance of MEG has changed materially over the past year. Twelve months ago the proposition centred on pending installations and future potential. FY26 provided clear commercial evidence.

\$9.7M

FY26 MEG revenue

From nil in FY25 - milestone-recognised on delivery

\$13.1M

Open MEG orders

In place entering FY27

6

Sales orders

\$30M of sales to date in the world's fastest-growing MEG market

2

Additional systems contracted for installation

Contracted for installation over the next 12 months

The U.S. opportunity

The United States is the world's largest MEG market. U.S. research hospitals are expected to begin ordering in FY27, with first installations anticipated in FY28 - supported by independent UCSD validation of Orion LifeSpan and FDA clearance obtained in 2020.

Commercial validation

Executed major installations demonstrate Compumedics can manufacture, deliver and commission complex high-value neuroimaging systems internationally.

Differentiated technology

Orion LifeSpan combines proprietary MEG hardware - the only dual adult/paediatric helmet - with CURRY, the established gold standard in neuroimaging software.

High barriers to entry

MEG requires specialised hardware, software, manufacturing expertise, clinical knowledge and long-term customer engagement - materially higher barriers than most medtech categories.

Expanding reference base

Each successful installation strengthens credibility with prospective customers; a concentrated market is won by reference sites.

FY27 priority MEG market expansion through U.S. commercial launch: deliver the \$13.1M order book to schedule and margin, build world-class reference sites, secure the first U.S. orders, and grow recurring software, support and lifecycle revenue attached to each installed system.

An established global business with a clear operational reset and differentiated technology upside

The near-term priority is operational performance. Management is focused on improving the efficiency, competitiveness and scalability of the underlying DWL business while continuing to support product innovation.

The core business

DWL is a recognised global provider of transcranial Doppler systems for non-invasive measurement of cerebral blood flow, with an established position in specialist neurological and neurocritical-care markets. FY26 revenue was \$4.5M, with strong U.S. performance.

Operational improvement

Improving the economics of the existing business is the central priority and precedes aggressive investment in adjacent opportunities: manufacturing continuity, cost reduction and sustainable margins.

Portfolio renewal

The Ez-Dop platform - FDA and EU MDR approved - provides an opportunity to strengthen the core hospital offering.

Robotic TCD - disciplined optionality

AI-enabled robotic TCD remains strategically attractive longer term. Reducing operator dependency could materially broaden clinical usability - one of the principal barriers to wider adoption. Development is aligned with clinical demand, regulatory milestones and clearly defined commercial returns.



Investor takeaway DWL combines an established specialist business with meaningful product innovation optionality, while management remains focused on improving the profitability and scalability of the core business.

A growing installed base drives durable, recurring revenue


FY26 revenue of \$8.1M, up 4%. Consumables, service and support generate recurring revenue across Compumedics' global installed base of more than 25,000 systems.

Embedded recurring revenue

Every Compumedics system generates demand for electrodes, sensors, disposables, service, maintenance and upgrades throughout its useful life - revenue that recurs independently of capital equipment sales cycles.

Attractive revenue characteristics

Repeat purchasing, high customer retention and attractive margins provide a predictable revenue base that grows alongside the installed fleet.



Installed base compounds the opportunity

More than 25,000 systems deployed globally provide a substantial platform for increasing consumables penetration, service attachment and revenue per installed system.

FY27 focus

Increase consumables and service attachment across the installed base, expand the NeuroMedical Supplies portfolio and increase penetration of disposable EEG products and other high-value accessories.

Investor takeaway Together with SaaS, consumables & customer care lifted recurring revenue to 30% of the FY26 total - a share that rises with every system installed.

SECTION 03

Why now & the path ahead

The evidence behind the thesis, how the business creates value, and the FY27 objective: further double-digit revenue growth, with EBITDA growing at a faster rate than revenue.



From promise to proof: FY26 put evidence behind every pillar of the investment thesis

	TWELVE MONTHS AGO	FY26 - DELIVERED	THE UPSIDE AHEAD
Growth	Revenue up 2% in FY25; the thesis rested on future execution	Record revenue \$60.3M, up 18.5% - 1.04x book-to-bill	Further double-digit revenue growth targeted in FY27
Earnings leverage	Prospective - EBITDA margin ~6%	EBITDA \$5.4M, up 74% - 4.0x the rate of revenue growth; margin ~9%	Margin recovery and scale economics remain early
Revenue quality	SaaS 12% of revenue; recurring 27%	SaaS \$10.2M, up 70% - recurring now 30% of revenue	Somfit D U.S. release ahead; recurring still a minority
MEG	Three systems awaiting delivery (~\$15M secured)	\$9.7M recognised - six sales orders in China; independently validated	\$13.1M open orders; U.S. entry expected from FY27
Cash & profit	Operating cash inflow \$0.4M; NPAT negative	\$6.6M inflow; NPAT positive - cash less the invoice financing facility and overdraft improved by \$6.7 million to \$5.6 million	Rising capacity to self-fund the growth agenda
U.S. execution	Commercial reset underway	Reset underway - new U.S. commercial leadership in place	Capital equipment recovery; Somfit expansion

Why now Four decades built a platform that is hard to replicate - proprietary technology, regulatory clearances, global distribution and a 25,000-system installed base - with several independent growth engines rather than one bet. FY26 proved that platform converts into growth, earnings leverage and cash, yet Compumedics still trades at ~1x revenue against the 4-8x common among comparable global healthtech peers.

How we create value: grow, improve the mix, leverage the base, convert to cash

01 Grow

+18.5%

Record FY26 revenue of \$60.3M; further double-digit growth targeted in FY27.

02 Improve the mix

30%

Of revenue now recurring (FY24: 25%), led by SaaS growing at 70%.

03 Leverage the base

4.0x

EBITDA grew at four times the rate of revenue; margin lifted to ~9%.

04 Convert to cash

\$6.6M

Operating cash inflow, up from \$0.4M; net cash improved by \$6.7M.

THE ENABLER - INSTITUTIONALISED EXECUTION

Performance discipline

Cost, margin and capital discipline embedded across the Group, enabling investment to be concentrated behind the highest-return growth opportunities.

Commercial execution

Strengthened leadership, accountability and go-to-market capability to unlock greater productivity from CMP's established products, channels and installed base.

Scalable operating platform

Systems, controls, supply chain and manufacturing capabilities being strengthened to support scale, margin expansion and cash generation.



The compounding effect Higher revenue + better mix + operating leverage + cash conversion = higher-quality earnings, stronger returns on capital and greater strategic flexibility.

Build on the progress: another year of profitable growth on the way to a larger, more recurring, more profitable company

“Compumedics remains focused on delivering further double-digit revenue growth in FY27, with EBITDA growth at a faster rate than revenue.”


- Compumedics Limited, Business Update, 25 August 2026

FY27 PRIORITIES

- **Grow Somfit in the U.S.** - expand home sleep testing; Somfit D toward U.S. release
- **Stay #1 in premium sleep labs** - defend the high end; convert \$18.2M of sleep orders
- **Expand MEG into the U.S. market** - deliver \$13.1M of MEG orders; win first U.S. orders
- **The enablers** - order book execution, U.S. capital equipment recovery, cost discipline

The FY26 exit position: \$28.3M of open orders | cash less the invoice financing facility and overdraft improved by \$6.7 million to \$5.6 million | 30% of revenue recurring | cost base reset

The close Proprietary technology created the opportunity. FY26 proved it converts into commercial scale, earnings growth and cash. FY27 is about building on that progress through disciplined execution.



THE DESTINATION

A larger, more predictable and more profitable global medical technology company - more recurring revenue, higher margins, balanced across the U.S., Asia-Pacific and Europe, funding its own innovation.

Structural tailwinds: the sleep-disorder market is projected to grow from ~\$39.4B (2024) toward ~\$113B by 2033; neurology devices from ~\$20.4B to ~\$40.4B by 2034.

This presentation has been prepared by Compumedics Limited (ACN 006 854 897) (CMP). It contains summary information about CMP and its activities current as at September 2026, including audited financial information for the year ended 30 June 2026. All figures are in Australian dollars (AU\$) unless otherwise stated; market estimates originally published in US dollars have been converted at US\$0.70 = AU\$1.00. This presentation was authorised for release by the Board of Compumedics Limited.

While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statements, including statements regarding FY27 revenue and EBITDA objectives. These forward-looking statements have been made based upon CMP's expectations and beliefs concerning future developments and their potential effect on CMP (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond CMP's control. No assurance is given that future developments will be in accordance with CMP's expectations. Actual results could differ materially from those expected by CMP.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular investment needs.

Thank you

Compumedics Limited (ASX: CMP) | Melbourne, Australia | compumedics.com.au

Dr David Burton

Executive Chairman & Chief Executive Officer

P: +61 3 8420 7300

David Lawson

Director & Chief Financial Officer

P: +61 3 8420 7300

39 years | 4 platforms | 60+ countries | \$60.3M of FY26 revenue, 30% of it recurring

